Literature DB >> 25517876

The impact of coronary artery disease on outcomes after liver transplantation.

Anton I Skaro1, Lorenzo G Gallon, Vadim Lyuksemburg, Colleen L Jay, Lihui Zhao, Daniela P Ladner, Lisa B VanWagner, Andre M De Wolf, James D Flaherty, Josh Levitsky, Michael M Abecassis, Mihai Gheorghiade.   

Abstract

AIMS: The aim of this study is to assess the impact of obstructive coronary artery disease (CAD) on outcomes after liver transplantation.
BACKGROUND: Patients considered for liver transplantation are at an increased risk for CAD. Obstructive CAD is a contraindication for liver transplantation at most centres. However, the association between severity of CAD and liver transplantation outcomes remains poorly characterized.
METHODS: We retrospectively reviewed 386 consecutive liver transplantations performed between January 2001 and December 2005 at Northwestern Memorial Hospital (NMH). A comparative analysis was conducted for a national cohort (n = 23 820) from the United Network for Organ Sharing database. Outcome measures included patient and graft survival, rates of acute myocardial infarction and heart failure.
RESULTS: Patient survival remained similar irrespective of CAD severity or cardiovascular risk index (CRI) in the NMH cohort. The CRI closely correlated with the presence of CAD in the NMH cohort [CRI 0, odds ratio (OR) 0.125, 95% confidence interval (95% CI) 0.02-0.61, P = 0.01; CRI 1, OR 1 reference; CRI ≥2, OR 2.28, 95% CI 1.09-4.75, P = 0.02]. In the national cohort using Cox regression, high (≥2) CRI (reference 0, hazard ratio 1.376, 95% CI 1.271-1.488, P < 0.0001) predicted patient mortality and exceeded established risk factors, including Hepatitis C virus (HCV) (hazard ratio 1.321, 95% CI 1.242-1.403, P < 0.0001), hepatocellular carcinoma (HCC) (hazard ratio 1.27, 95% CI 1.181-1.370, P < 0.0001) and diabetes (hazard ratio 1.241, 95% CI 1.160-1.326, P < 0.0001).
CONCLUSION: Liver transplantation in patients with CAD is not associated with prohibitive risk for cardiac events and patient mortality. Appropriately treated CAD should therefore not represent a contraindication to liver transplantation.

Entities:  

Mesh:

Year:  2016        PMID: 25517876     DOI: 10.2459/JCM.0000000000000207

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  10 in total

1.  Outcome of Liver Transplant Recipients With Revascularized Coronary Artery Disease: A Comparative Analysis With and Without Cardiovascular Risk Factors.

Authors:  Sanjaya K Satapathy; Jason M Vanatta; Ryan A Helmick; Albert Flowers; Satish K Kedia; Yu Jiang; Bilal Ali; James Eason; Satheesh P Nair; Uzoma N Ibebuogu
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

2.  Pretransplant diabetes mellitus predicts worse outcomes of liver transplantation: evidence from meta-analysis.

Authors:  P Li; H Fan; Q He
Journal:  J Endocrinol Invest       Date:  2017-06-30       Impact factor: 4.256

3.  Mind the Gap: Statin Underutilization and Impact on Mortality in Liver Transplant Recipients.

Authors:  Patrick T Campbell; Lisa B VanWagner
Journal:  Liver Transpl       Date:  2019-10       Impact factor: 5.799

4.  The relationship between coronary artery disease and cardiovascular events early after liver transplantation.

Authors:  Samarth S Patel; Fei-Pi Lin; Viviana A Rodriguez; Chandra Bhati; Binu V John; Taylor Pence; Mohammad B Siddiqui; Adam P Sima; Antonio Abbate; Trevor Reichman; Mohammad S Siddiqui
Journal:  Liver Int       Date:  2019-03-26       Impact factor: 5.828

5.  A Holistic Clustering Methodology for Liver Transplantation Survival.

Authors:  Lisiane Pruinelli; György J Simon; Karen A Monsen; Timothy Pruett; Cynthia R Gross; David M Radosevich; Bonnie L Westra
Journal:  Nurs Res       Date:  2018 Jul/Aug       Impact factor: 2.381

Review 6.  The comparative and added prognostic value of biomarkers to the Revised Cardiac Risk Index for preoperative prediction of major adverse cardiac events and all-cause mortality in patients who undergo noncardiac surgery.

Authors:  Lisette M Vernooij; Wilton A van Klei; Karel Gm Moons; Toshihiko Takada; Judith van Waes; Johanna Aag Damen
Journal:  Cochrane Database Syst Rev       Date:  2021-12-21

7.  Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: An evaluation of the evidence and consensus recommendations.

Authors:  Lisa B VanWagner; Matthew E Harinstein; James R Runo; Christopher Darling; Marina Serper; Shelley Hall; Jon A Kobashigawa; Laura L Hammel
Journal:  Am J Transplant       Date:  2017-11-18       Impact factor: 8.086

Review 8.  Cardiac and Pulmonary Vascular Risk Stratification in Liver Transplantation.

Authors:  Blessing Aghaulor; Lisa B VanWagner
Journal:  Clin Liver Dis       Date:  2020-10-26       Impact factor: 6.126

9.  The diagnostic and prognostic utility of risk factors defined by the AHA/ACCF on the evaluation of cardiac disease in liver transplantation candidates.

Authors:  Sarah Alexander; Meron Teshome; Hena Patel; Edie Y Chan; Rami Doukky
Journal:  BMC Cardiovasc Disord       Date:  2019-05-02       Impact factor: 2.298

Review 10.  Cardiac Risk Assessment in Liver Transplant Candidates: Current Controversies and Future Directions.

Authors:  Pranab M Barman; Lisa B VanWagner
Journal:  Hepatology       Date:  2021-06       Impact factor: 17.298

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.